Prostate cancer biomarkers: Technical advances and clinical implications
Poster Session 46
-
Location:Room Stockholm, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session Investigations on circulating tumor cells have been widely used in prostate cancer biomarker studies. Further improvements in biomarker assessment include application of MRI. New technical tools will be presented in the session.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, 3University of Michigan, Dept. of Radiology, Ann Arbor, United States of America
Institutes: 1Universitätsklinikum Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, 2Proteomedix, Dept. of Biotechnology, Schlieren, Switzerland, 3Cantonal Hospital St. Gallen, Dept. of Oncology, St. Gallen, Switzerland
Institutes: 1Oslo University Hospital and University of Oslo, Institute of Cancer Research and Institute of Clinical Medicine, Oslo, Norway, 2Norwegian University of Science and Technology (NTNU), Dep. of Circulation and Medical Imaging, Trondheim, Norway, 3Oslo University Hospital, Institute of Cancer Research, Oslo, Norway, 4St.Olav’s Hospital and Norwegian University of Science and Technology (NTNU), Dep. of Urology and Dep. of Circulation and Medical Imaging, Trondheim, Norway, 5Oslo University Hospital, Dep. of Pathology, Oslo, Norway, 6Oslo University Hospital, Dep. of Urology, Oslo, Norway, 7Oslo University Hospital, Institute of Informatics, Oslo, Norway
Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, 2University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 3Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, 4University of Montreal Health Center, Dept. of Surgery, Section of Urology, Montreal, Canada
Institutes: 1Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, 2The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, 3AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, 4Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, 5Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
Institutes: 1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Vita-Salute University, San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy, 3University of Montreal, Health Centre, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 4Pitié-Salpétrière Hospital, Dept. of Urology, Paris, France
Institutes: 1Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, 2Kitasato University School of Medicine, Dept. of Radiology and Radiation Oncology, Sagamihara, Japan
Institutes: 1Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, 2Universitair Ziekenhuis Gent, Dept. of Radiation Oncology and Experimental Cancer Research, Ghent, Belgium
Institutes: 1Aichi Medical University, Dept. of Urology, Nagakute, Japan, 2Aichi Medical University, Dept. of Tumor Immunology, Nagakute, Japan, 3Aichi Medical University, Division of Advanced Research Promotion, Nagakute, Japan
Institutes: 1Oslo University Hospital/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer, Oslo, Norway, 2Oslo University Hospital, Dept. of Tumorbiology, Oslo, Norway, 3Centre For Molecular Medicine (Norway), University of Oslo and Oslo University Hospital, Dept. of Prostate Cancer, Oslo, Norway, 4University of Oslo, Dept. of Biosciences, Oslo, Norway, 5Oslo University Hospital, Dept. of Cancer Registry of Norway, Oslo, Norway, 6University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom, 7University of Cambridge, Translational Prostate Cancer Group, Cambridge, United Kingdom, 8Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 9University of Oxford, Dept. of Surgical Sciences, Oxford, United Kingdom, 10Queen’s University Belfast/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer UK/Movember Centre of Excellence For Prostate Cancer Research, Centre For Cancer Research and Cell Biology, Belfast, Ireland